Lantern Pharma Inc. (Nasdaq: LTRN)

Lantern Pharma, Inc. is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action, and also rescuing or revitalizing abandoned or failed cancer drugs using machine learning techniques, genomic data and precision oncology trials. Lantern Pharma recognizes that the high cost and low success rates in oncology drug development largely stem from the inability to appropriately stratify patient populations prior to enrollment, and also from the inability to fully elucidate mechanisms of action that can suggest potent combinations. Our approach which leverages our RADR platform helps to provide rapid, meaningful insight to both...

Biotechnology,cancer drug development,precision medicine,biomarkers,genetic screen,companion diagnostics,precisiononcology,artificial intelligence,patient stratification,drug rescue,and drug repurposing

Lantern pharma inc. (nasdaq: ltrn) operates in the Biotechnology research industry.

Lantern pharma inc. (nasdaq: ltrn)'s revenue is 11m - 100m

Lantern pharma inc. (nasdaq: ltrn) has 11 - 50 employees.